USE OF A COMPOSITION CONTAINING AN EXTRACT OF TULIPA GESNERIANA

Abstract

New compositions containing an extract of Tulipa Gesneriana. The compositions include a tulip extract from the Tulipa Gesneriana family, acetyl-tetrapeptide-2, and acetyl-hexapeptide-51 amide. Also, the use thereof in cosmetics, and the use thereof in pharmaceuticals, particularly in dermatology for treating or preventing skin aging, and the use thereof in pharmaceuticals, particularly in dermatology, for treating or preventing pathologies linked to oxidative stress.

Claims

1-26. (canceled)

27. A combination comprising or consisting of the following three ingredients: a tulip extract from the Tulipa Gesneriana family, and acetyl-tetrapeptide-2, and acetyl-hexapeptide-51 amide.

28. The combination according to claim 27, wherein the combination comprises hyaluronic acid whose molecular weight is between 20 and 50 kDa.

29. The combination according to claim 27, wherein the combination comprises maltodextrin.

30. The combination according to claim 27, comprising or consisting of the following four ingredients: a tulip extract from the Tulipa Gesneriana family, and acetyl-tetrapeptide-2, and acetyl-hexapeptide-51 amide, hyaluronic acid whose molecular mass is between 20 and 50 kDa, and optionally maltodextrin.

31. The combination according to claim 27, wherein the tulip extract comprises 20 to 70% of sugars, and 15 to 30% of phenolic compounds, of which at least 8% phenolic compounds are flavonoids, in percentage by weight relative to the total weight of the dry extract, said flavonoids comprise 50 to 90% of quercetin and 10 to 50% of kampferol, in percentage by weight relative to the total weight of flavonoids.

32. The combination according to claim 27, wherein the quantity of the tulip extract is greater than 0% and less than or equal to 5%, as a percentage by weight relative to the total weight of the combination.

33. The combination according to claim 27, wherein the quantity of acetyl-tetrapeptide-2 is between 0.005 and 0.05%, in percentage by weight relative to the total weight of the combination.

32. The combination according to claim 27, wherein the quantity of acetyl-hexapeptide-51 amide is between 0.005 and 0.05%, as a percentage by weight relative to the total weight of the combination.

33. The combination according to claim 27, wherein the quantity of yaluronic acid is between 1 and 25%, as a percentage by weight relative to the total weight of the combination.

34. The combination according to claim 27, comprising or consisting of: a tulip extract from the Tulipa Gesneriana family, at a rate of 0.1 to 5%, as a percentage by weight relative to the total weight of the combination, and acetyl-tetrapeptide-2, at a rate of 0.005 to 0.05%, as a percentage by weight relative to the total weight of the combination, and acetyl-hexapeptide-51 amide, at a rate of 0.005 to 0.05%, as a percentage by weight relative to the total weight of the combination.

35. The combination according to claim 27, comprising or consisting of: a tulip extract from the Tulipa Gesneriana family, at a rate of 0.1 to 5%, as a percentage by weight relative to the total weight of the combination, and acetyl-tetrapeptide-2, at a rate of 0.005 to 0.05%, as a percentage by weight relative to the total weight of the combination, and acetyl-hexapeptide-51 amide, at a rate of 0.005 to 0.05%, as a percentage by weight relative to the total weight of the combination, hyaluronic acid, at a rate of 1 to 25%, as a percentage by weight relative to the total weight of the combination.

36. A cosmetic composition, comprising a combination according to claim 27, in a cosmetically acceptable medium.

37. A dermatological composition, comprising, as an active substance, a combination according to claim 27, with a pharmaceutically acceptable excipient.

38. The dermatological composition according to claim 37, wherein said dermatological composition is formulated for topical application.

39. A method for treating or preventing pathologies linked to oxidative stress, wherein the method comprises the use of the combination according to claim 27, or a dermatological composition, comprising, as an active substance, said combination, with a pharmaceutically acceptable excipient.

40. A cosmetic method for treating or preventing skin aging, comprising the application to a healthy skin of a cosmetic composition according to claim 27.

41. The method of treatment according to claim 40, wherein said composition is applied from 1 to 3 times a day to cleansed skin.

42. The combination according to claim 27, wherein the tulip extract from the Tulipa Gesneriana family is a purple tulip extract.

43. The Combination according to claim 42, comprising or consisting of: a purple tulip extract, at a rate of 0.1 to 5%, as a percentage by weight relative to the total weight of the combination, and acetyl-tetrapeptide-2, at a rate of 0.005 to 0.05%, as a percentage by weight relative to the total weight of the combination, and acetyl-hexapeptide-51 amide, at a rate of 0.005 to 0.05%, as a percentage by weight relative to the total weight of the combination.

44. The combination according to claim 42, comprising or consisting of: a purple tulip extract, at a rate of 0.1 to 5%, as a percentage by weight relative to the total weight of the combination, and acetyl-tetrapeptide-2, at a rate of 0.005 to 0.05%, as a percentage by weight relative to the total weight of the combination, and acetyl-hexapeptide-51 amide, at a rate of 0.005 to 0.05%, as a percentage by weight relative to the total weight of the combination, hyaluronic acid, at a rate of 1 to 25%, as a percentage by weight relative to the total weight of the combination.

Description

FIGURES

[0217] FIG. 1 represents an explanation of the analysis of the images according to example 10.

[0218] FIG. 1A represents an image of an immunostaining, in which a corresponds to the labeled structure.

[0219] FIG. 1B shows label detection, where b represents the label, selected by pixel thresholding.

[0220] FIG. 1C represents the determination of the region of interest, by manual tracing, in the case of the epidermis c.

[0221] FIG. 1D represents the combination of FIGS. 1B and 1C, in which d represents the labeling in the epidermis.

[0222] FIG. 2 represents the evaluation of hyaluronic acid in the epidermis (EpiD) and the papillary dermis (DP) of example 10B. [0223] TF=very weak, F=weak, M=moderate, AN=fairly clear, N=clear, TN=very clear, Fo=strong.

[0224] FIG. 3 represents the evaluation of elastin in the papillary dermis of example 10C. [0225] TF=very weak, F=weak, M=moderate, AN=fairly clear, N=clear, TN=very clear, Fo=strong.

[0226] FIG. 4 represents the evaluation of collagen I in the papillary dermis of example 10D. [0227] TF=very weak, F=weak, M=moderate, AN=fairly clear, N=clear, TN=very clear, Fo=strong.

EXAMPLES

Definition of Trademarks

[0228]

TABLE-US-00003 Trademarks INCI Name Dumaflorine ® Maltodextrin, Tulipa gesneriana Maltodextrin, Tulipa gesneriana flower extract flower extract Juveleven ™ Butylene glycol/Aqua/acetyl Butylene glycol/Aqua/acetyl hexapeptide-51 amide hexapeptide-51 amide Uplevity ™ Aqua/Acetyl Tetrapeptide- Water/Acetyl Tetrapeptide- 2/caprylyl glycol 2/caprylyl glycol Dow Corning ® Cyclopentasiloxane/Dimethicone Cyclopentasiloxane/Dimethicone 9040 Crosspolymer Crosspolymer Regu ®-Seb Serenoa Serrulata Fruit saw palmetto extract, sesame Extract/Sesamum Indicum seed oil, argan oil, phytosterol, (Sesame) Seed Oil/Argania tocopherol Spinosa Kernel Oil/Beta- Sitosterol/Tocopherol Sepigel 305 ™ Polyacrylamide/C13-14 Polyacrylamide/C13-14 Isoparaffin/Laureth-7 Isoparaffine/Laureth-7 Easynov ™ Octyldodecanol/Octyldodecyl Octyldodecanol/Octyldodécyl Xyloside/PEG-30 Xyloside/PEG-30 Dipolyhydroxystearate Dipolyhydroxystearate Uvinul ® MS40 Benzophenone-4 Sulisobenzone Eusolex ® 6300 Methylbenzylidene Camphor methylbenzylidene camphor Eusolex ® 232 Phenylbenzimidazole Sulfonic Phenylbenzimidazole Sulfonic Acid Acid Tinosorb ® M Methylene Bis-Benzotriazolyl Methylene Bis-Benzotriazolyl Tetramethylbutylphenol (and) Tetramethylbutylphenol (and) Aqua (and) Decyl Glucoside Aqua (and) Decyl Glucoside (and) Propylene Glycol (and) (and) Propylene Glycol (and) Xanthan Gum Xanthan Gum Uvinul ® N35 Etocrylene Etocrylene Uvinul ® 539 Octocrylene Octocrylene Parsol ® 1789 Butyl Methoxydibenzoylmethane Avobenzone Uvasorb ® HEB Diethylhexyl Butamido Triazone Iscotrizinol Uvinul ® T150 Ethyl hexyl triazone Ethylhexyltriazone Tinosorb ® Bis-Ethylhexyloxyphenol Bis-ethylhexyloxyphenol Methoxyphenyl Triazine Methoxyphenyl Triazine Tween ®-60 Polysorbate 60 Polysorbate 60 Tween ®-20 Polysorbate 20 Polysorbate 20 Sepigel ™ 305 Polyacrylamide & C13-14 Polyacrylamide, C13-14 Isoparaffin & Laureth-7 Isoparaffine, Laureth-7 Primalhyal ™ 50 Hydrolyzed Hyaluronic Acid Hydrolyzed Hyaluronic Acid Sepimax Zen ™ Polyacrylate Crosspolymer-6 Polyacrylate Crosspolymer-6 Euxyl ® K900 Benzyl Alcohol, Benzyl Alcohol, Ethylhexylglycerin, Tocopherol Ethylhexylglycerin, Tocopherol

[0229] Example 1: Evaluation of the ex vivo anti-aging activity of a cream and a serum

[0230] A cream and a serum comprising Dumaflorine®, Uplevity™ and Juveleven™ are prepared and tested ex vivo on explanted human skin.

[0231] 12 Explants of human skin are prepared from a plasty taken from a person over the age of 40. The explants are left to survive at 37° C. in an atmosphere enriched with 5% CO.sub.2.

[0232] The products are applied topically at a rate of 2mg/cm.sup.2 and the treatment is renewed every two days.

[0233] The application of the products was carried out on three explants per product tested.

[0234] Six control explants were also prepared, including three plasticized controls (frozen at D0 ) and three untreated controls, undergoing the same survival as the treated explants.

[0235] The controls receive no treatment, or are treated with the excipient.

[0236] At D0, the three explants of the plasty control are removed and frozen at −80° C.

[0237] At D10, three explants from each batch are removed and frozen at −80° C.

[0238] The anti-aging activity is evaluated on the 12 explants by: [0239] A viability check after staining [0240] Staining of elastin [0241] Immunolabelling of collagen I [0242] Immunolabeling of hyaluronic acid

Histological treatments

[0243] The frozen samples are cut at 7 μm for immunostaining.

[0244] Viability check. Paraffin sections are stained. A viability review is performed. Explants treated with cream or serum show, after 10 days, good viability of dermal and epidermal structures

Immunolabelling of Collagen I

[0245] Collagen I is highlighted on sections thanks to a specific antibody.

[0246] The explants treated with the cream or the serum show, after 10 days, an increase in the expression of collagen I, compared to the controls.

Immunolabelling of HABP

[0247] HABP is highlighted on sections thanks to a specific antibody.

[0248] After 10 days, an increase in the fluorescence is observed at the level of the epidermis of the skin samples treated with the cream or the serum, compared with the controls.

Elastin Staining

[0249] Elastin is highlighted on sections thanks to a specific stain.

[0250] The explants treated with the cream or the serum show, after 10 days, an increase in the expression of elastin, compared to the controls.

[0251] Example 2: Study of the in vivo anti-aging activity of a cream and a serum

[0252] A cream and a serum comprising Dumaflorine®, Uplevity™ and Juveleven™ are prepared and tested in vivo on a panel of 20 volunteers, half-face.

[0253] Different assessments are carried out: [0254] Evaluation of wrinkles, by projection of fringes [0255] Evaluation of mechanical properties by cutometer [0256] Taking pictures of the face [0257] A self-assessment questionnaire targeting the effect felt, the effectiveness and the cosmetic quality of the product.

Selection of Volunteers

[0258] The volunteers are recruited from the general population: subjects aged 45 to 65 with, in particular, wrinkles and fine lines around the crow's feet.

[0259] Course of the study

[0260] Day 0 (D0) [0261] Discounts of the product to use and the satisfaction questionnaire [0262] Performing biometrological measurements on each half-face: [0263] projection of fringes [0264] Cutometer [0265] Pictures

[0266] Day 1 to Day 28 (D1 to D28) [0267] application of the product daily on the half-face.

[0268] Day 28 (D28) [0269] Verification of the running of the study [0270] Performing biometrological measurements on each half-face: [0271] projection of fringes [0272] Cutometer [0273] Pictures

[0274] Day 28 to Day 56 (D28 to D56) [0275] application of the product daily on the half-face.

[0276] Day 56 (D56) [0277] Verification of the running of the study [0278] Performing biometrological measurements on each half-face: [0279] projection of fringes [0280] Cutometer [0281] Pictures [0282] Return of the questionnaire and return of the products

Evaluation of Mechanical Properties

[0283] The evaluation of the mechanical properties makes it possible to study the functional level of the tissue structures responsible for the firmness of the skin:

[0284] Elastic structures (elastic fibers, curvature of connective bundles, folding of the stratum comeum)

[0285] Structures with viscous behavior (interstitial fluids, internal adhesions).

[0286] The study is carried out by the cutometer whose measurements are based on the principle of the suction method by creating a negative pressure (between 20 and 500 mbar) carried out in a cylindric “chamber”. Successive cycles of suction-release programmed in the software make it possible, after each measurement, to record the graph of the deformation as a function of time and then to obtain by a cursor system all the desired extension parameters.

[0287] Schematically, the resistance of the skin to being deformed by negative pressure during the suction phase measures skin tone, while its ability to return to its original position during the relaxation phase measures skin elasticity.

[0288] Conventionally, 3 parameters measuring ratios are taken into account: [0289] RO, representing the firmness of the skin. It is the passive behavior of the skin in relation to the force applied. [0290] R6 during the suction phase measuring the visco-elastic properties of the skin (if skin elasticity improves, this R6 ratio will decrease) [0291] R7 during the relaxation phase measuring the pure biological elasticity of the skin (if skin elasticity improves, this R7 ratio will increase).

Taking Pictures

[0292] Facial photographs are taken and wrinkles are analyzed.

[0293] The present in vivo study demonstrated the effectiveness of the cream and serum tested.

[0294] Example 3: Study of the effects of a combination comprising Dumaflorine®, Uplevity™ and Juveleven™

[0295] A combination comprising Dumaflorine®, Uplevity™ and Juveleven™ was used and tested in vitro. Protection of the DNA of cells against damage caused by benzo[a]pyrene, a persistent pollutant contained in cigarette smoke or automobile exhaust, has been observed.

[0296] The combination has been used and tested in vivo. Significant repair of UV DNA damage was observed.

[0297] Example 4: Study of the effects of a combination comprising Dumaflorine®, Uplevity™ and Juveleven™

[0298] A combination comprising Dumaflorine®, Uplevity™ and Juveleven™ has been used and tested in vivo on mature skin. An increase in firmness was observed, as well as an improvement in the integrity of the dermis (assessed by ballistometry and confocal microscopy).

[0299] Example 5: oil-in-water emulsion cream

TABLE-US-00004 TABLE 3 Oil-in-water emulsion cream composition Phase Ingredient INCI m/m % A Water Aqua QSP 100 Glycerin Glycerin 3 Glyceryl Glyceryl stearate 12 stearate Cetyl alcohol Cetyl alcohol 2 Ceteareth-20 Ceteareth-20 2 Dumaflorine ® Maltodextrin, Tulipa gesneriana 0.2 flower extract Juveleven ™ Butylene glycol/Aqua/acetyl 2 hexapeptide-51 amide Uplevity ™ Aqua/Acetyl Tetrapeptide-2/ 1 caprylyl glycol B Caprylic/capric Caprylic/capric triglyceride 8 triglyceride Argan oil Argania Spinosa Oil 1 sweet almond Prunus dulcis oil 1 oil C Phenoxyethanol Phenoxyethanol 0.1

[0300] Example 6: gel cream

TABLE-US-00005 TABLE 4 gel cream composition Phase Ingredient INCI m/m % A Dow Cyclopentasiloxane/Dimethicone 6 Corning ® 9040 Crosspolymer apricot oil Prunus Armeniaca kernel oil 2 Regu ®-Seb Serenoa Serrulata Fruit Extract/ 3 Sesamum Indicum (Sesame) Seed Oil/Argania Spinosa Kernel Oil/ Beta-Sitosterol/Tocopherol Sepigel 305 ™ Polyacrylamide/C13-14 Isoparaffin/ 3 Laureth-7 B Water Aqua 82.6 Dumaflorine ® Maltodextrin, Tulipa gesneriana 0.4 flower extract Juveleven ™ Butylene glycol/Aqua/acetyl 2 hexapeptide-51 amide Uplevity ™ Aqua/Acetyl Tetrapeptide-2/ 1 caprylyl glycol

[0301] Example 7: Water-in-oil cosmetic milk

TABLE-US-00006 TABLE 5 Water-in-oil cosmetic milk composition Phase Ingredient INCI m/m % A Water Aqua 64.5 Glycerin Glycerin 3 Xanthan gum Xanthan gum 1 Glyceryl Glyceryl stearate 12 stearate shea butter Butyrospermum parkii butter 2 Easynov ™ Octyldodecanol/Octyldodecyl 4 Xyloside/PEG-30 Dipolyhydroxystearate Dumaflorine ® Maltodextrin, Tulipa gesneriana 0.4 flower extract Juveleven ™ Butylene glycol/Aqua/acetyl 2 hexapeptide-51 amide Uplevity ™ Aqua/Acetyl Tetrapeptide-2/ 1 caprylyl glycol B Caprylic/capric Caprylic/capric triglyceride 4 triglyceride Isopropyl Isopropyl myristate 4 myristate Argan oil Argania Spinosa Oil 1 sweet almond Prunus dulcis oil 1 oil C Phenoxyethanol Phenoxyethanol 0.1

[0302] Example 8: oil-in-water emulsion cream comprising hyaluronic acid

TABLE-US-00007 TABLE 6 Oil-in-water emulsion cream composition Phase Ingredient INCI m/m % A Water Aqua QSP 100 Glycerin Glycerin 3 Glyceryl Glyceryl stearate 12 stearate Cetyl alcohol Cetyl alcohol 2 Ceteareth-20 Ceteareth-20 2 Dumaflorine ® Maltodextrin, Tulipa gesneriana 0.2 flower extract Juveleven ™ Butylene glycol/Aqua/acetyl 2 hexapeptide-51 amide Uplevity ™ Aqua/Acetyl Tetrapeptide-2/ 1 caprylyl glycol Hyaluronic acid Hyaluronic acid 1 B Caprylic/capric Caprylic/capric triglyceride 8 triglyceride Argan oil Argania Spinosa Oil 1 sweet almond Prunus dulcis oil 1 oil C Phenoxyethanol Phenoxyethanol 0.1

[0303] Example 9: Water-in-oil cosmetic milk comprising hyaluronic acid

TABLE-US-00008 TABLE 7 Water-in-oil cosmetic milk composition Phase Ingredient INCI m/m % A Water Aqua 64.5 Glycerin Glycerin 3 Gomme Xanthane Xanthan gum 1 Glyceryl Glyceryl stearate 12 stearate shea butter Butyrospermum parkii butter 2 Easynov ™ Octyldodecanol/Octyldodecyl 4 Xyloside/PEG-30 Dipolyhydroxystearate Dumaflorine ® Maltodextrin, Tulipa gesneriana 0.4 flower extract Juveleven ™ Butylene glycol/Aqua/acetyl 1 hexapeptide-51 amide Uplevity ™ Aqua/Acetyl Tetrapeptide-2/ 1 caprylyl glycol Hyaluronic acid Hyaluronic acid 1 B Caprylic/capric Caprylic/capric triglyceride 4 triglyceride Isopropyl Isopropyl myristate 4 myristate Argan oil Argania Spinosa Oil 1 sweet almond Prunus dulcis oil 1 oil C Phenoxyethanol Phenoxyethanol 0.1

[0304] Example 10: Evaluation of the anti-aging action

[0305] 2 compositions, a cream according to example 5 (P1) and a serum (P2), were prepared and tested on ex vivo human skin explants.

TABLE-US-00009 Phase Ingredient INCI m/m % A Water Aqua 89.8 isopentyldiol isopentyldiol 5.0 Dumaflorine ® Maltodextrin, Tulipa gesneriana 0.3 flower extract Primalhyal ™ 50 Hydrolyzed Hyaluronic Acid 0.1 B Sepimax Zen ™ Polyacrylate Crosspolymer-6 0.3 C Euxyl ® K900 Benzyl Alcohol, Ethylhexylglycerin, 1.5 Tocopherol Juveleven ™ Butylene glycol/Aqua/acetyl 2.0 hexapeptide-51 amide Uplevity ™ Aqua/Acetyl Tetrapeptide-2/ 1.0 caprylyl glycol

Preparation of Explants

[0306] 12 explants 12±1 mm in diameter were prepared from a plasty of a 60-year-old woman (reference P2258-AB60).

[0307] The explants were left to survive in BEM medium (BIO-EC's Expiants Medium) at 37° C. in a humid atmosphere, enriched with 5% CO2.

Distribution of Explants

[0308] The explants were divided into 4 batches as indicated in Table 9:

TABLE-US-00010 Batch Designation Treatment Explants number Sample T0 Plasty control none 3 D0 T Non treated none 3 D10 control P1 Composition P1 P1 3 D10 P2 Composition P2 P2 3 D10

Application of products

[0309] At D0 , D2, D4, D7 and D9, the P1 and P2 products were applied topically, at a rate of 2 μl per explant (2 mg/cm.sup.2) and spread using a spatula.

[0310] The explants of batches T did not receive any treatment, except renewal of the medium.

[0311] Half of the medium was renewed (1 ml per well) at D2, D4, D7 and D9.

Specimens

[0312] At D0 , the 3 explants of batch T0 were removed and cut in half.

[0313] One part was fixed in buffered formalin solution, and the other was frozen at −80° C.

[0314] At D10, 3 explants from each batch were collected and treated in the same way as at D0 .

Histological Treatments

[0315] After 24 hours in buffered formalin, the samples were dehydrated and impregnated with paraffin using a Leica PEARL dehydration machine. They were blended using a Leica EG 1160 embedding station.

[0316] 5 μm sections were made using a Minot type microtome, Leica RM 2125 and mounted on Superfrost® histological glass slides.

[0317] 7 μm sections were made from the frozen samples using a Leica CM 3050 cryostat and mounted on Superfrost®Plus histological glass slides.

[0318] The microscopic observations were carried out by optical microscopy, using a Leica type DMLB or Olympus BX43 or BX63 microscope.

[0319] The shots were taken with an Olympus DP72 or DP74 camera and cellSens software.

Image Analysis

[0320] Image analyzes were performed on all photos from each batch using cellSens Olympus software.

[0321] For each batch of explants, the percentage of surface of the region of interest covered by the marking (percentage of marked surface) is determined by an image analysis according to FIG. 1.

[0322] The percentage of marked surface (Surf%) for each treatment is compared to the condition T=>P vs T.

[0323] Example 10A: viability check after staining with Masson's trichrome

[0324] The cellular viability of the epidermal and dermal structures was observed on paraffin sections after staining with Masson's trichrome variant of Goldner.

[0325] It was assessed by microscopic examination.

[0326] Cell viability for all batches is shown in Table 10:

TABLE-US-00011 TABLE 10 cell reliability results Cell viability Batch Epiderm Derm T0 B B TD10 AB B P1D10 AB B P2D10 AB B morphology caption: B = good, AB = Fair

[0327] Example 10B: immunostaining of hyaluronic acid by HABP

[0328] Labeling of hyaluronic acid was carried out on paraffin sections with a biotinylated HABP (hyluronic acid binding protein) (amsbio, ref. AMS.HKD.BC41) diluted 1/800th in PBS-BSA 0.3%, for 1 hour at room temperature, then amplified with a biotin/streptavidin system and revealed in VIP, a purple peroxidase substrate (Vector laboratories, SK-4600).

[0329] Immunolabelling was performed manually, evaluated by microscopic observation and semi-quantified by image analysis.

[0330] The evaluation of hyaluronic acid (HABP) in the epidermis (EpiD) and the papillary dermis (DP) of all batches is in FIG. 2:

In Living Epidermis

[0331] On the control batch T0 , the labeling of hyaluronic acid is clear in the living epidermis.

[0332] On the control batch TD10, the synthesis of hyaluronic acid is moderate to fairly clear in the living epidermis.

[0333] Effect of product application on hyaluronic acid synthesis, compared to batch TD10: [0334] The P1 composition induces a slight increase [0335] The P2 composition induces a moderate increase.

In the Papillary Dermis

[0336] On the control group T0 , the labeling of hyaluronic acid is clear in the papillary dermis.

[0337] On the TD10 control batch, hyaluronic acid synthesis is moderate to fairly clear in the papillary dermis.

[0338] Effect of products on hyaluronic acid synthesis, compared to batch TD10: [0339] The P1 composition induces a slight increase [0340] The P2 composition does not induce any modification.

[0341] The percentage of surface occupied by hyaluronic acid (HABP) in the living epidermis of all batches is shown in Table 11:

TABLE-US-00012 TABLE 11 T0 TD10 P1D10 P2D10 Mean 36.3 18.1 24.5 30.5 Standard Deviation 7.4 6.2 7.0 6.8

[0342] The percentage of surface occupied by hyaluronic acid (HABP) in the papillary dermis of all batches is shown in Table 12:

TABLE-US-00013 TABLE 12 T0 TD10 P1D10 P2D10 Mean 74.3 44.1 57.1 41.9 Standard Deviation 6.3 7.1 12.1 11.7

[0343] Example 10C: immunostaining of elastin

[0344] Elastin was labeled on paraffin sections with a polyclonal anti-elastin antibody (Novotec, ref. 25011), diluted to 1/100th in PBS-BSA 0.3%-Tween 20 at 0.05% for 1 hour at temperature ambient and revealed in AlexaFluor488 (Lifetechnologies, ref. Al 1008). The nuclei were counterstained with propidium iodide.

[0345] Immunolabeling was performed using an immunolabeling automaton (Dako, AutostainerPlus), evaluated by microscopic examination and semi-quantified by image analysis.

[0346] Elastin labeling in the papillary dermis of all batches is shown in FIG. 3.

[0347] The percentage of surface occupied by elastin in the papillary epidermis of all batches is shown in Table 13:

TABLE-US-00014 T0 TD10 P1D10 P2D10 Mean 13.6 13.0 14.2 10.3 Standard Deviation 3.6 3.9 3.0 1.6

[0348] Example 10D: immunostaining of collagen I

[0349] Collagen I was labeled on frozen sections with an anti-collagen I polyclonal antibody (Monosan, ref. PS047), diluted to 1/100th in 0.05% PBS-BSA 0.3%-Tween 20 for 1 hour at room temperature and revealed in AlexaFluor488 (Lifetechnologies, ref. Al 1008).

[0350] The nuclei were counterstained with propidium iodide.

[0351] Immunolabeling was performed using an immunolabeling automaton (Dako, AutostainerPlus), evaluated by microscopic examination and semi-quantified by image analysis.

[0352] The evaluation of collagen I in the papillary dermis of all batches is shown in FIG. 4:

[0353] The percentage of surface occupied by elastin in collagen I of all batches is shown in the

[0354] Table 14:

TABLE-US-00015 TABLE 14 T0 TD10 P1D10 P2D10 Mean 85.6 59.9 73.9 80.6 Standard Deviation 10.1 15.2 10.2 9.6

[0355] In conclusion, the “day cream” (P1) composition shows anti-aging activity, by inducing an increase in hyaluronic acid both in the living epidermis and in the papillary dermis as well as an increase in collagen I after 10 days of treatment.

[0356] The “serum composition” (P2) shows anti-aging activity, inducing an increase in hyaluronic acid in the living epidermis as well as an increase in collagen I after 10 days of treatment.